Research graph
References from A contract research organization perspective on secondary pharmacology: current practices, panel selection, and emerging needs for interpretation. Local targets link to admitted publications; unresolved targets remain external evidence.
De-risking seizure liability: Integrating adverse outcome pathways (AOPs), new approach methodologies (NAMs), and in silico approaches while highlighting knowledge gaps
10.1093/toxsci/kfaf109 · 2025 · External reference
Safety screening in early drug discovery: An optimized assay panel
10.1016/j.vascn.2019.106609 · 2019 · External reference
Reducing safety-related drug attrition: The use of in vitro pharmacological profiling
10.1038/nrd3845 · 2012 · External reference
The state of the art in secondary pharmacology and its impact on the safety of new medicines
2024 · External reference
In vitro pharmacologic profiling aids systemic toxicity assessment of chemicals
10.1016/j.taap.2024.117131 · 2024 · External reference
In vitro pharmacology working group: the in vitro pharmacology working group
2024 · External reference
Rationalizing secondary pharmacology screening using human genetic and pharmacological evidence
10.1093/toxsci/kfy265 · 2019 · External reference
Aggregation and analysis of secondary pharmacology data from investigational new drug submissions at the US Food and Drug Administration
10.1016/j.vascn.2021.107098 · 2021 · External reference
Unresolved reference
External reference
Unresolved reference
2005 · External reference
A practical guide to secondary pharmacology in drug discovery
10.1016/j.vascn.2020.106869 · 2020 · External reference
Potential functional and pathological side effects related to off-target pharmacological activity
10.1016/j.vascn.2017.02.020 · 2017 · External reference
Secondary pharmacology data to assess potential off-target activity of new drugs: A regulatory perspective
10.1038/nrd3845-c1 · 2015 · External reference
Regulatory forum review*: Utility of in vitro secondary pharmacology data to assess risk of drug-induced Valvular heart disease in humans: Regulatory considerations
10.1177/0192623317690609 · 2017 · External reference
Secondary pharmacology across therapeutic modalities: A cross-modality principle-based framework for off-target assessment
2026 · External reference
Shaping secondary pharmacology panels of the future: Evolving target selection criteria for safety panels
10.1038/s41573-025-01184-7 · 2025 · External reference
Analysis of secondary pharmacology assays received by the US Food and Drug Administration
10.1016/j.vascn.2022.107205 · 2022 · External reference
A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs
10.1038/s41467-023-40064-9 · 2023 · External reference
Unresolved reference
2017 · External reference
Revisiting ICH S7A after 25 years: Outcomes of a multi-stakeholder workshop and strategic pillars for modernizing safety pharmacology
10.1016/j.yrtph.2026.106096 · 2026 · External reference
Results from an EFPIA, JPMA, PhRMA industry survey on reopening and revamping the ICH S7A guidance on safety and secondary pharmacology
10.1016/j.vascn.2025.107763 · 2025 · External reference
2000–2023 over two decades of ICH S7A: Has the time come for a revamp?
10.1016/j.yrtph.2023.105368 · 2023 · External reference
Points to consider for revising the ICH S7A guideline on safety and secondary pharmacology
10.1016/j.yrtph.2025.105795 · 2025 · External reference
The neuroscience of drug reward and addiction
10.1152/physrev.00014.2018 · 2019 · External reference
Keynote review: In vitro safety pharmacology profiling: An essential tool for successful drug development
10.1016/s1359-6446(05)03632-9 · 2005 · External reference
